Table 2.
Cell type | Cell dose |
Cell-related adverse effects after transplantation |
% Mortality (number of deaths/total number) after transplantation |
||
---|---|---|---|---|---|
< 24 hours | >24 hours | <24 hours | >24 hours | ||
cbMNCs |
10 × 106 |
None |
None |
0 (Nonsignificant) |
8% (2/24) (Nonsignificant) |
cmMSCs |
10 × 106 |
3/6 animals developed severe inflammation in ipsilateral eye |
None |
100% (6/6) *P < 0.0001 |
_ |
5 × 106 |
1/23 animals developed severe inflammation in ipsilateral eye |
None |
0 (Nonignificant) |
26% (6/23) (Nonsignificant) |
|
cbMSCs | 5 × 106 | None | None | 0 (Nonsignificant) | 11% (2/18) (Nonsignificant) |
Adverse effects and mortality after cell transplantation. The table shows cell-related adverse effects within 24 hours and >24 hours of cell transplantation. Both cbMNC- and cbMSC-group animals had no adverse effects after cell transplantation. One animal transplanted with 5 × 106 cmMSCs and three animals transplanted with 10 × 106 cmMSCs had severe inflammation of the ipsilateral eye within 24 hours of transplantation. The mortality rate was calculated, for two time points, within 24 hours and >24 hours, as a percentage of animals that died to the total animals in each group. A decreasing trend in mortality was seen in the cbMNC and cbMSC groups, but not in the cmMSC group compared with the PBS group. The mortality rate within 24 hours of transplantation in animals transplanted with 10 × 106 cmMSCs was significantly higher compared with the PBS group animals (P < 0.0001). *P value relative to the PBS group calculated with the Fisher Exact test. Significance was ascertained at P < 0.05.